DCK Antibody | 62-650

DCK Antibody | 62-650 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: This DCK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 171-200 amino acids from the C-terminal region of human DCK.

Research Area: Cancer, Signal Transduction

Tested Application: WB, IHC-P, IF, IP

Application: For IHC-P starting dilution is: 1:10~50
For IF starting dilution is: 1:10~50
For WB starting dilution is: 1:1000
For IP starting dilution is: 1:500~1000

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 31 kDa

Validation: N/A

Isoform: N/A

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis

Clonality: Polyclonal

Clone: N/A

Isotype: Rabbit Ig

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.

Concentration: batch dependent

Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Deoxycytidine kinase, dCK, DCK

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Deoxycytidine kinase is responsible for the phosphorylation of several deoxyribonucleosides and their analogs. Deficiency of this enzyme activity is associated with resistance to antiviral and anticancer chemotherapeutic agents, whereas increased enzyme activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. It is the rate limiting enzyme in the activation of many important anticancer and retroviral drugs and its activity is often decreased in cells that are resistant to cytosine arabinoside.